In the 1990s, on the back of other therapies for estrogen-dependent tumors, many studies focused on the use of tamoxifen, a selective estrogen receptor inhibitor (SERM), in the HCC setting. This evidence concerns the gene ESR1 and hepatocellular carcinoma.